What's Happening?
Researchers at Georgetown’s Lombardi Comprehensive Cancer Center have identified the receptor for advanced glycation end-products (RAGE) as a significant factor in worsening breast cancer outcomes in older patients. The study, conducted on mouse models
and human breast cancers, found that RAGE amplifies inflammatory signaling, which increases with metastatic progression. The research suggests that inhibiting RAGE could serve as an adjunctive therapy for older breast cancer patients. The study highlights the role of aging in altering the host environment, influencing immune function and chronic inflammation, which in turn affects cancer behavior.
Why It's Important?
This research addresses a critical gap in understanding how aging impacts cancer progression, particularly breast cancer metastasis. By identifying RAGE as a mechanistic link between aging and cancer spread, the study provides a potential therapeutic target for improving outcomes in older patients. As age is a primary risk factor for breast cancer, with higher mortality rates in older women, targeting RAGE could lead to more effective treatments and improved survival rates. The findings emphasize the need for age-specific cancer research and therapies.
What's Next?
A clinical study is underway at Lombardi evaluating the RAGE inhibitor TTP488 in breast cancer patients, focusing on safety and cognitive outcomes. Given its favorable safety profile, TTP488 could be repurposed for cancer treatment, offering a well-tolerated option for older patients. Further research will likely explore the broader application of RAGE inhibitors in other age-related diseases, potentially leading to new strategies for managing cancer and other inflammatory conditions in the elderly.
